This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

As obesity rates in the United States have reached 41.9 percent among adults, Xevant has released a new e-book, Navigating Obesity Care and GLP-1 Coverage: A Guide for Employers, designed to empower ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

A study found that disruptions in homeostasis from quick weight reduction by consuming GLP-1 drug can elevate cortisol - a ...

New drugs from public and private companies are ... These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion ...

From loss of skin elasticity to hair density, supplements that offer targeted support for GLP-1 users, as well as those that ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

Ozempic doesn't just reduce weight. Research shows GLP-1s also changes how much people spend on food, and the types of food ...

Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...